Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

The analysts expect launches of medicines including Eli Lilly’s Zepbound and Novo Nordisk’s Wegovy to help add $20 billion to the value of the market ... GlobalData’s analysis starts in ...

“The impact of Wegovy on the obesity market has been huge. key opinion leaders (KOLs) interviewed by GlobalData defined it as ‘revolutionary’. Now with Zepbound, the revolution continues ...

CVS’s decision directly threatens a sizable portion of Zepbound’s addressable market. The potential impact of CVS's formulary decision regarding Zepbound may be somewhat limited. Lilly ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... chiefly that it was not a blinded analysis and participants knew which medication they ...

According to Bloomberg, the 47% greater weight loss with Zepbound included around two more inches off patients’ waists, a difference researchers told the news outlet can impact blood pressure ...

A new study has found that people taking Eli Lilly's obesity drug Zepbound lost almost 50% more weight than those using Novo Nordisk's Wegovy. The study, published in the New England Journal of ...

People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly-sponsored study, compared with a 13.7% loss for Wegovy patients, Lilly said Wednesday.